Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd) . Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
Product Specifications
CAS Number
1826843-81-5
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
Approximately 45.42 kDa
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Antibody-Drug Conjugates (ADCs)
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15129046 1 Vial
Lentiviral human PRIMPOL shRNA (UAS) - Lentiviral human PRIMPOL shRNA (UAS, GFP) plasmid
Ask
View Details MBS1260390-01 0.02 mg (E-Coli)
Recombinant Streptococcus sanguinis Ketol-acid reductoisomerase (ilvC)
Ask
View Details MBS1260390-02 0.02 mg (Yeast)
Recombinant Streptococcus sanguinis Ketol-acid reductoisomerase (ilvC)
Ask
View Details 
MBS1260390-03 0.1 mg (E-Coli)
Recombinant Streptococcus sanguinis Ketol-acid reductoisomerase (ilvC)
Ask
View Details MBS1260390-04 0.1 mg (Yeast)
Recombinant Streptococcus sanguinis Ketol-acid reductoisomerase (ilvC)
Ask
View Details MBS1260390-05 0.02 mg (Baculovirus)
Recombinant Streptococcus sanguinis Ketol-acid reductoisomerase (ilvC)
Ask
View Details